Patents by Inventor Eyal Fisher

Eyal Fisher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230016954
    Abstract: The invention provides assays and methods for diagnosing and treating infectious diseases. The invention relates in some embodiments to urinary biomarkers and their use in the differential diagnosis of bacterial and viral infections. The invention further relates to means for determining and providing correct treatment to infection in a non-invasive manner, while minimizing antibiotic misuse.
    Type: Application
    Filed: December 10, 2020
    Publication date: January 19, 2023
    Inventors: Shani Shenhar-Tsarfaty, Shlomo Avraham Berliner, Ori Rogowski, Eyal Fisher, Adi Silberman
  • Publication number: 20230003742
    Abstract: The invention provides assays and methods for detecting and monitoring systemic inflammation Particularly, the invention in embodiments thereof relates to the use of urinary biomarkers for non-invasive determination of the level of inflammation.
    Type: Application
    Filed: December 10, 2020
    Publication date: January 5, 2023
    Inventors: Shani Shenhar-Tsarfaty, Shlomo Avraham Berliner, Ori Rogowski, Eyal Fisher, Adi Silberman, Yishai Levin
  • Publication number: 20200402613
    Abstract: The present invention provides a computer-implemented method for detecting cell-free DNA (cfDNA), such as circulating tumour DNA, in a DNA-containing sample obtained from a patient, the method comprising: (a) providing loci of interest comprising at least 2 mutation-containing loci representative of a tumour of the patient (“patient-specific loci”); (b) providing sequence data comprising sequence reads of a plurality of polynucleotide fragments from a DNA-containing sample from the patient, wherein said sequence reads span said at least 2 mutation-containing loci of step (a); (c) optionally, performing reads collapsing to group the sequence reads into read families; (d) calculating the mutant allele fraction across some or all of said at least 2 patient-specific loci, optionally wherein the mutant allele fraction is calculated by aggregating mutant reads and total reads; (e) classifying the sample as containing or not containing the target cfDNA based on the calculated mutant allele fraction.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 24, 2020
    Inventors: Eyal Fisher, Katrin Heider, Charles Massie, Florent Mouliere, Nitzan Rosenfeld, Christopher G. Smith, Jonathan C.M. Wan